Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
36 hedge funds and large institutions have $20.9M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
16% more funds holding
Funds holding: 31 → 36 (+5)
15% more capital invested
Capital invested by funds: $18.2M → $20.9M (+$2.69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAM
Krensavage Asset Management
New York
|
+$958K |
| 2 |
Renaissance Technologies
New York
|
+$422K |
| 3 |
AG
Algert Global
San Francisco,
California
|
+$366K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$300K |
| 5 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$729K |
| 2 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$255K |
| 3 |
BlackRock
New York
|
-$133K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$124K |
| 5 |
SIM
Spark Investment Management
New York
|
-$59.9K |
JNP Hedge Fund Activity: Q4 2017 in Review
36 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q4 2017, worth a combined $20.9M — up 15% from $18.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JNP positions and 3 closed out — a net gain of 5 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Krensavage Asset Management, adding an estimated $958K. The largest seller was Heartland Advisors, cutting an estimated $729K.
- 36 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q4 2017, up from 31 in Q3 2017.
- Funds reported $20.9M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 15% quarter-over-quarter.
- 8 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 3 closed out, a net change of +5 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was Krensavage Asset Management, an estimated $958K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Heartland Advisors, an estimated $729K sold.
Based on aggregated 13F filings for Q4 2017.